Business Context and Reporting Period
Company: TOMI Environmental Solutions, Inc. (TOMZ)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2025
Business Overview: TOMI is a global provider of disinfection and decontamination solutions using proprietary Binary Ionization Technology (BIT). The flagship product, SteraMist, utilizes ionized Hydrogen Peroxide (iHP) to treat indoor environments. Operations are organized into four divisions: Life Sciences, Hospital-Healthcare, Food Safety, and Commercial. The company serves customers including Fortune 100 pharmaceutical firms, government agencies (NASA, CDC, USDA), and healthcare systems.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $5,636 | $7,739 |
| Gross Profit | $3,077 | $3,557 |
| Gross Margin | 54.6% | 46.0% |
| Net Loss | $(3,749) | $(4,477) |
| Operating Expenses | $6,931 | $7,662 |
| Cash and Cash Equivalents (Year-End) | $88 | $665 |
| Working Capital | $1,024 | $3,772 |
| Total Debt (Convertible Notes) | $2,912 | $2,360 |
| Accumulated Deficit | $(58,052) | $(54,303) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 27% to $5.6 million, primarily due to the timing of large equipment purchases that occurred in 2024. Product revenue dropped $2.1 million, while service revenue remained relatively flat.
- Margin Improvement: Gross margin improved to 54.6% from 46.0%. This increase was largely driven by a $1.1 million inventory reserve recorded in 2024, which did not recur in 2025. Underlying margins remained relatively stable.
- Expense Reduction: Total operating expenses decreased 10% to $6.9 million. Selling expenses dropped 31% due to lower commissions and marketing spend. General and administrative expenses fell 11%, aided by a significant reduction in credit loss expense ($267k in 2025 vs. $1.1M in 2024).
- Liquidity Deterioration: Cash on hand declined to $88,000, and working capital decreased by $2.7 million. Accounts receivable dropped $1.2 million, and inventory decreased $652,000 following write-offs.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Pipeline
Management highlights a strong commercial pipeline despite revenue headwinds. As of year-end, the company reported:
- Integration Pipeline: Approximately $3 million in active SIS and CES integration projects, with $1.6 million awarded and $800,000 recognized since late November.
- Broader Pipeline: Management-tracked opportunities exceeded $18 million, with quoted opportunities of approximately $11 million.
- Backlog: Sales backlog grew to approximately $1.8 million.
- Strategic Wins: Secured a $500,000 purchase order from a global biopharmaceutical leader and adoption by a leading Cell and Gene Therapy manufacturer.
Going Concern and Liquidity Plan
The filing states there is substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses, negative cash flows, and an accumulated deficit of $58.1 million. Management's plan to address this includes:
- Equity Line of Credit (ELOC): A $20 million ELOC with Hudson Global Ventures became effective in December 2025. A first draw of $94,130 was executed in February 2026.
- Convertible Notes: Evaluating options to convert outstanding debt to equity or repay using ELOC proceeds.
- Cost Management: Continued reduction of operating expenses and implementation of a customer deposit policy to improve cash flow.
Risks and Contingencies
- Nasdaq Deficiencies: The company is subject to two concurrent deficiency proceedings: (1) Closing bid price below $1.00 for 30 consecutive days (compliance deadline May 18, 2026); and (2) Stockholders' equity below $2.5 million (compliance deadline May 20, 2026). Failure to comply may result in delisting.
- Internal Controls: Material weaknesses in internal control over financial reporting were identified, including limited resources with GAAP expertise and ineffective review policies. Remediation is ongoing but not fully complete as of year-end.
- Customer Concentration: One customer accounted for approximately 10% of 2025 revenue. The company has no long-term customer contracts.
- Debt Obligations: Outstanding convertible notes total $3.1 million principal (12% interest), convertible at $1.25/share. Interest payments create recurring cash obligations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $88,000 cash balance against monthly burn rates and the timing of future ELOC draws.
- Nasdaq Compliance: Monitor stock price performance and equity levels to assess the risk of delisting before May 2026 deadlines.
- Pipeline Conversion: Assess the likelihood of converting the $18 million pipeline and $3 million integration projects into recognized revenue in 2026.
- Debt Conversion: Evaluate the risk of dilution if convertible notes ($3.1M principal) are converted at the $1.25 strike price, especially if the stock price recovers.
- Internal Controls: Review progress on remediation of material weaknesses in financial reporting to ensure future financial statement reliability.